86 related articles for article (PubMed ID: 27494881)
1. Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Cattaneo F; Patrussi L; Capitani N; Frezzato F; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncotarget; 2016 Aug; 7(35):57086-57098. PubMed ID: 27494881
[TBL] [Abstract][Full Text] [Related]
2. A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients.
Rossi S; Tatangelo V; Dichiara M; Butini S; Gemma S; Brogi S; Pasquini S; Cappello M; Vincenzi F; Varani K; Lopresti L; Malchiodi M; Carrara C; Gozzetti A; Bocchia M; Marotta G; Patrussi L; Carullo G; Baldari CT; Campiani G
Biomed Pharmacother; 2024 May; 174():116537. PubMed ID: 38579402
[TBL] [Abstract][Full Text] [Related]
3. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
4. Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway.
Cheng B; Li L; Luo T; Wang Q; Luo Y; Bai S; Li K; Lai Y; Huang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):67. PubMed ID: 38429845
[TBL] [Abstract][Full Text] [Related]
5. STAT4 expression and activation is increased during mitosis in vitro and in vivo in skin- and mucosa-derived cell types: implications in neoplastic and inflammatory skin diseases.
Ferreli C; Lai C; August S; Buggy Y; Kumar P; Brownlow N; Parker P; Friedmann PS; Ardern-Jones M; Pickard C; Healy E
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1663-1673. PubMed ID: 28516569
[TBL] [Abstract][Full Text] [Related]
6. Targeting the NTSR2/TrkB oncogenic pathway in chronic lymphocytic leukemia.
Ikhlef L; Yassine M; Chandouri B; Rivière L; Naves T; Dmytruk N; Gachard N; Jauberteau MO; Gallet PF
Sci Rep; 2024 Mar; 14(1):6084. PubMed ID: 38480783
[TBL] [Abstract][Full Text] [Related]
7. Aberrant activation of p53/p66Shc-mInsc axis increases asymmetric divisions and attenuates proliferation of aged mammary stem cells.
Priami C; Montariello D; De Michele G; Ruscitto F; Polazzi A; Ronzoni S; Bertalot G; Binelli G; Gambino V; Luzi L; Mapelli M; Giorgio M; Migliaccio E; Pelicci PG
Cell Death Differ; 2022 Dec; 29(12):2429-2444. PubMed ID: 35739253
[TBL] [Abstract][Full Text] [Related]
8. p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formation.
Lopresti L; Capitani N; Tatangelo V; Tangredi C; Boncompagni G; Frezzato F; Visentin A; Marotta G; Ciofini S; Gozzetti A; Bocchia M; Trentin L; Baldari CT; Patrussi L
Front Cell Dev Biol; 2024; 12():1297116. PubMed ID: 38389706
[No Abstract] [Full Text] [Related]
9. The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL.
Otte M; Stachelscheid J; Glaß M; Wahnschaffe L; Jiang Q; Lone W; Ianevski A; Aittokallio T; Iqbal J; Hallek M; Hüttelmaier S; Schrader A; Braun T; Herling M
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173993
[TBL] [Abstract][Full Text] [Related]
10. p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-κB.
Tatangelo V; Boncompagni G; Capitani N; Lopresti L; Manganaro N; Frezzato F; Visentin A; Trentin L; Baldari CT; Patrussi L
Front Oncol; 2022; 12():877495. PubMed ID: 35847884
[TBL] [Abstract][Full Text] [Related]
11. CCR7 in Blood Cancers - Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target.
Cuesta-Mateos C; Terrón F; Herling M
Front Oncol; 2021; 11():736758. PubMed ID: 34778050
[TBL] [Abstract][Full Text] [Related]
12. LncRNA Hmrhl regulates expression of cancer related genes in chronic myelogenous leukemia through chromatin association.
Choudhury SR; Dutta S; Bhaduri U; Rao MRS
NAR Cancer; 2021 Dec; 3(4):zcab042. PubMed ID: 34734184
[TBL] [Abstract][Full Text] [Related]
13. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.
Cuesta-Mateos C; Brown JR; Terrón F; Muñoz-Calleja C
Front Immunol; 2021; 12():662866. PubMed ID: 33841445
[TBL] [Abstract][Full Text] [Related]
14. P66Shc: A Pleiotropic Regulator of B Cell Trafficking and a Gatekeeper in Chronic Lymphocytic Leukemia.
Patrussi L; Capitani N; Baldari CT
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32325830
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Selective B Cell Autophagy by the Pro-oxidant Adaptor p66SHC.
Onnis A; Cassioli C; Finetti F; Baldari CT
Front Cell Dev Biol; 2020; 8():193. PubMed ID: 32274384
[TBL] [Abstract][Full Text] [Related]
16. STAT4: an immunoregulator contributing to diverse human diseases.
Yang C; Mai H; Peng J; Zhou B; Hou J; Jiang D
Int J Biol Sci; 2020; 16(9):1575-1585. PubMed ID: 32226303
[TBL] [Abstract][Full Text] [Related]
17. p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.
Rosenquist R
Haematologica; 2019 Oct; 104(10):1914-1916. PubMed ID: 31575671
[No Abstract] [Full Text] [Related]
18. p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
Patrussi L; Capitani N; Ulivieri C; Manganaro N; Granai M; Cattaneo F; Kabanova A; Mundo L; Gobessi S; Frezzato F; Visentin A; Finetti F; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Leoncini L; Efremov DG; Baldari CT
Haematologica; 2019 Oct; 104(10):2040-2052. PubMed ID: 30819907
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
